EUVIMEDEUVIMED entdecken
Multizentrische Studie

Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort

Makito Miyake, Nobutaka Nishimura, Yuki Oda, Tatsuki Miyamoto, Kota Iida, Kuniaki Inoue, Akira Tachibana, Takanosuke Yoshikawa, Keichi Sakamoto, Mikiko Ohnishi, Fumisato Maesaka, Norimi Takamatsu und 14 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02573-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Makito Miyake und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. makitomiyake@yahoo.co.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsHumansMaleFemaleAgedMiddle AgedJapanAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellProgression-Free SurvivalUrologic NeoplasmsRetrospective StudiesAdultEast Asian People

Stichwörter der Autor:innen

AvelumabChemotherapyKidney pelvisPembrolizumabUreterUrinary bladder neoplasms

Substanzen

Antibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitorspembrolizumabavelumab

Autor:innen und Institutionen

  • Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan. makitomiyake@yahoo.co.jp.
  • Department of Urology, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara, 634-8522, Japan.
  • Department of Urology, Hirao Hospital, Kashihara, Nara, Japan.
  • Department of Urology, Takai Hospital, Tenri, Nara, Japan.
  • Department of Urology, Tane General Hospital, Osaka, Japan.
  • Department of Urology, Osaka Gyoumeikan Hospital, Osaka, Japan.

Zitieren

APA

Miyake, M., Nishimura, N., Oda, Y., Miyamoto, T., Iida, K., Inoue, K., Tachibana, A., Yoshikawa, T., Sakamoto, K., Ohnishi, M., Maesaka, F., Takamatsu, N., Mieda, K., Ohmori, C., Matsubara, T., Tomizawa, M., Shimizu, T., Ohnishi, K., Hori, S., …, & Nara Urological Research and Treatment Group (2024). Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02573-5

Vancouver

Miyake M, Nishimura N, Oda Y, Miyamoto T, Iida K, Inoue K, et al. Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02573-5

BibTeX
@article{Miyake2024,
  author = {Miyake, Makito and Nishimura, Nobutaka and Oda, Yuki and Miyamoto, Tatsuki and Iida, Kota and Inoue, Kuniaki and Tachibana, Akira and Yoshikawa, Takanosuke and Sakamoto, Keichi and Ohnishi, Mikiko and Maesaka, Fumisato and Takamatsu, Norimi and Mieda, Kosuke and Ohmori, Chihiro and Matsubara, Toshihiko and Tomizawa, Mitsuru and Shimizu, Takuto and Ohnishi, Kenta and Hori, Shunta and Morizawa, Yosuke and Gotoh, Daisuke and Nakai, Yasushi and Torimoto, Kazumasa and Tanaka, Nobumichi and Fujimoto, Kiyohide and Nara Urological Research and Treatment Group, Nara Urological Research and Treatment Group},
  title = {Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohort},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02573-5}
}
Kostenlos starten →